Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001140361-25-005536 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | ADMA | Tade Brad L. | CFO, Treas | A - Grant | $0.00 | +62.2K | 261.7K | +31% | $0 |
| D | 2025-02-21 | 2025-02-19 | ADMA | Tade Brad L. | CFO, Treas | A - Grant | $0.00 | +93.0K | 93.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-19 | A | A | 62,227 | $0.00 | 261,660 | D | — | — | (F1) These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date. (F3) (continued from footnote 2) (iii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; (F2) Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; (F4) (continued from footnote 3) (iv) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (v) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs. |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-19 | A | A | 93,023 | $0.00 | 93,023 | D | $16.07 · — to 2035-02-19 | 93,023 Common Stock | (F5) The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan. |